Anti-PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) Monoclonal Antibody(Clone: PDL1/2746)
|Amount :||100 µg|
|Isotype :||Mouse IgG2b, kappa|
|Content :||200 µg/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.|
|Storage condition :||Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.|
PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.
ELISA (For coating, order antibody without BSA); Western Blot (1-2µg/ml);Flow Cytometry (1-2µg/million cells); Immunofluorescence (1-2µg/ml);Immunohistochemistry (Formalin-fixed) (1-2µg/ml for 30 minutes at RT),(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.
For Research Use Only. Not for use in diagnostic/therapeutics procedures.